China approved CARsgen’s satricabtagene autoleucel (satri-cel) for solid tumors, marking what the company says is the first CAR-T authorization in the category for a specific solid-tumor target. The National Medical Products Administration (NMPA) greenlit the therapy in Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma after at least two prior lines. The approval is tied to clinical results that CARsgen described as delivering a progression-free survival benefit and an acceptable safety profile compared with physician’s choice chemotherapy. CAR-T therapy in solid tumors has historically faced barriers to approval, largely due to efficacy and safety challenges in the tumor microenvironment. CARsgen also outlined a preconditioning regimen combining low-dose nab-paclitaxel with lymphodepleting chemotherapy as part of the treatment approach. With gastric cancer representing a high disease burden in Asia and China contributing a large share of global cases, the regulatory decision expands the solid-tumor CAR-T footprint beyond hematologic indications. The approval is likely to reshape cost, logistics, and target selection discussions for CAR-T developers pursuing next lines of solid tumor combinations.